Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin).
Two patients with Cushing's syndrome due to lung carcinoid tumours were given the long-acting somatostatin analogue SMS 201-995 (Sandostatin). One received a single 50 micrograms dose which produced a 50% reduction in circulating ACTH levels within 4 h. The other has been maintained in clinical and biochemical remission for 10 weeks on 100 micrograms tid. This is the first report of the successful use of SMS 201-995 in carcinoid-induced Cushing's syndrome, and suggests that this hormone analogue could be valuable in the long term medical management of such patients.
Hearn
P R
PR
Department of Biological Research, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Reynolds
C L
CL
Johansen
K
K
Woodhouse
N J
NJ
D000324:Adrenocorticotropic Hormone / Q000097:blood*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002276:Carcinoid Tumor / Q000097:blood* / Q000150:complications; D003480:Cushing Syndrome / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D006854:Hydrocortisone / Q000097:blood*; D008175:Lung Neoplasms / Q000097:blood* / Q000150:complications; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D000324:Adrenocorticotropic Hormone; D015282:Octreotide; D006854:Hydrocortisone